Infertility treatment heads first drugs on FDA’s new priority review scheme
The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority …
Post
-
-
FDA greenlight for Roche’s Alzheimer’s disease test sparks care paradigm shift
The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost therapeutic intervention options …
-
ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase …
-
ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC
At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results …
-
ESMO25: Padcev/Keytruda combo has potential as new SOC for perioperative bladder cancer
Results from the Phase III registrational EV-303/KEYNOTE-905 study evaluating the combination of Pfizer’s and Astellas’ nectin-4 targeting antibody-drug conjugate Padcev …
-
ESMO25: Keytruda combo defies doubt, delivers PFS and OS gains in ovarian cancer
Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than …
-
Market dynamics for generics must change amid ANDA pilot debut
The US Food and Drug Administration’s (FDA’s) pilot scheme to expedite the review of US-made generic medicines is welcomed but …
-
Adcytherix gains $122m to propel ADC development
France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the antibody-drug conjugate (ADC) pipeline …
-
EMD Serono partners US government to widen IVF access
Merck’s healthcare division in Canada and the US, EMD Serono, has signed an agreement with the Trump administration to expand …
-
AstraZeneca doubles Lokelma output with $445m Texas plant expansion
AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to …
-
Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
Danish pharma giant Novo Nordisk has inked a definitive deal with Omeros Corporation to acquire its late-stage-ready rare disease asset, …
-
From Nobel to next-gen: Sweden’s quiet life sciences ascent
Sweden’s place on the frontier of science has a long history, with the capital Stockholm coming to a standstill every …
-
Bavarian Nordic’s shareholders and board in standoff amid takeover offer
Bavarian Nordic’s board of directors has urged shareholders to accept a sweetened takeover offer as the potential sale of the …
-
Tubulis closes $361m in Series C to advance cancer treatment
Tubulis has completed a Series C financing round, securing €308m ($361m) that will primarily be directed towards advancing clinical development …
-
Oceanpine Capital to acquire 80% equity stake in Beijing Jacoray
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for a total consideration of 200m …
